• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Dry Lake Diary 20-Feb-02


Food and Drug Administration

Seattle District

Pacific Region

22201 23rd Drive SE

Bothell, WA 98021-4421

Telephone: 425-486-8788

FAX: 425-483-4996

February 20, 2002



In reply refer to Warning Letter SEA 02-33


Larry J. Vanderstelt, Co-Owner

Dry Lake Dairy

12492 Big Foot Road

Nampa, Idaho 83486

Dear Mr. Vanderstelt:

An investigation at your dairy located 12492 Big Foot Road, Nampa, Idaho, by our

investigator on January 10, 2002, that you offered an animal for sale for slaughter as

food in violation of Section 402(a)(3)( and 402(a)(4) of the Federal Food, Drug, and

Cosmetic Act (the Act).

A food is adulterated under Section 402(a)(2)( c)(ii) of the Act if it contains a new animal drug that is unsafe within the meaning of Section 512 of the Act. On or about November 9, 2001, you sold a cow to [redacted], who in turn identified the cow with back tag#9588 and sold to [redacted]. This cow, identified with back tag #9588, was identified on USDA lab report #428327. USDA analysis of tissue samples collected from that animal identified the presence of 5.89 parts per million (PPM) of sulfadimethoxine in the muscle

Tissue, 5.40 parts per million (PPM) of sulfadimethoxine in the liver tissue. The allowable tolerance for sulfadimethoxine in the uncooked edible tissue of cattle is 0.1 PPM.

A food is adulterated under Section 40 of the Act "if it has been prepared, packed, or held

under insanitary conditions.. whereby have been rendered injurious to health." As it

applies in this case, "insanitary conditions means that you hold animals which are ultimately offered for sale for slaughter as food u which are so inadequate that medicated

animals bearing possibly harmful drug residues are likely to enter the food supply.

For example, our investigator noted the following conditions on your farm:

1. You failed to have a system in place to assure that all treated animals had treatment records which should include:

a. the animal? s identity

b. the date of treatment

c. the drug administered

d. the dosage administered and

e. the drug pre-slaughter withdrawal time

2. A failure to follow label directions for the medication (sulfadimethoxine) you administered to your animals in that either you or your staff administered the product in excess of the recommended dosage, or you failed to follow the labeled pre-slaughter withdrawal time.

3. You failed to have a system in place to assure that the treated calf was withheld from

slaughter in accordance with instructions for use of the drug.

We request that you take prompt action to ensure that dairy cows and calves, which you offer for sale as human food, will not be adulterated with drugs or contain illegal residues.

Introducing adulterated foods into interstate commerce is a violation of Section 30l(a) of the Act. Causing the adulteration of drugs after receipt in interstate commerce is a violation of Section 301(k) of the Act.

You should be aware that it is not necessary for you to have personally shipped an adulterated animal into interstate commerce to be responsible for a violation of the Act. The fact that you offered an adulterated animal to be slaughtered into food for human consumption where it was held for sale in interstate commerce is efficient to make you responsible for violations of the Act.

Our investigation revealed that the residue came from your use of Albon, which contains

sulfadimethoxine. The dosage and withdrawal times provided by the manufacturer of

the Albon is intended to withdrawal time information, which you are required

instructions can be considered off label use. Off label use of veterinary drugs is a deviation Title 21, Code of Federal Regulations (21 CFR), Part 530.

Within fifteen (15) days of the receipt, notify this office in writing of the specific steps you have taken to correct these violations and preclude their recurrence. If corrective action cannot be completed within fifteen working days, state the reason for the delay and the time frame within which corrections will be completed.

Please send your reply to the Food and Drug Administration, Bruce Williamson,

Compliance Officer, 22201 23rd Drive SE, Bothell, WA 98021. If you have questions regarding any issue in this letter, please contact Bruce Williamson, Compliance Officer, (425) 483-4976.


Charles M. Breen

District Director